Here's my take:
1. Great result "60% reduction in death" which was "the pre-specified endpoint of cardiac death"
2. But "no reduction in non-fatal recurrent decompensated heart failure events, which was the trials primary endpoint"
Point 2 worried me until rereading, specifically "This suggests that rexlemestrocel-L reduces mortality by mechanisms that are distinct from those of existing drugs that reduce hospitalization rates but do not significantly impact cardiac mortality"
I interpret this to mean that there is no real benefit over existing medications in terms of recurring events, BUT a huge benefit of 60% of not dying from the disease.
If I have interpreted this correctly, then I'll take those odds any day.
- Forums
- ASX - By Stock
- Ann: Mesoblast Phase 3 Chronic Heart Failure Results
Here's my take:1. Great result "60% reduction in death" which...
-
- There are more pages in this discussion • 934 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.15 |
Change
0.000(0.00%) |
Mkt cap ! $1.295B |
Open | High | Low | Value | Volume |
$1.15 | $1.16 | $1.11 | $4.890M | 4.306M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 96885 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.15 | 57099 | 40 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 108356 | 1.145 |
17 | 180166 | 1.140 |
15 | 265985 | 1.135 |
16 | 270625 | 1.130 |
13 | 586336 | 1.125 |
Price($) | Vol. | No. |
---|---|---|
1.150 | 51870 | 35 |
1.155 | 164852 | 22 |
1.160 | 68981 | 17 |
1.165 | 90735 | 10 |
1.170 | 58428 | 5 |
Last trade - 13.10pm 26/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |